Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
Exploratory study to examine the effect(s) of Imatinib mesylate treatment on life threatening
rare diseases with known associations to one or more Imatinib mesylate -sensitive tyrosine
kinases, and to identify the contribution of specific protein tyrosine kinases (PTKs) of that
specific disease.